secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001104659-23-125356
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics sells IL-1ß antibody assets to AlmataBio for $500K cash plus up to $70M milestones
--------------------------------------------------------------------------------

- Entered into Asset Purchase Agreement with AlmataBio for IL-1ß antibodies FL-101 and FL-103.
- Received $500,000 cash at closing; potential milestone payments up to $70 million tied to regulatory and sales milestones.
- Buyer assumed all liabilities related to the transferred assets.
- 80% of after-tax net proceeds from sale to be paid to former Flame Biosciences equityholders as additional merger consideration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923125356/0001104659-23-125356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923125356/tm2332656d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-125356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer